12:00 AM
 | 
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

P58: Phase I

In a U.K. Phase I trial of 20 healthy male volunteers, doses of 80-2400 mg of P58 were well tolerated, with no significant safety issues noted in either young...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >